COVID-19：イベルメクチン､無症状者に効果：レバノン､カタール､イラク（動画）：
Middle East COVID-19 Ivermectin Asymptomatic Group Faster than Controls:
中东 COVID-19 研究表明，伊维菌素治疗无症状人群的速度比对照组快
ー中東のCOVID-19 無作為化比較調査ー
レバノン、カタール、イラクの研究者グループ：
研究チームは、「無症候性の COVID-19 症例におけるイベルメクチンの効果」を調べました。
研究チームは、複数の大学の研究者チームで構成。
1) イベルメクチン治療群と
2) 比較対照群に分け
2 つのグループで観察しました。
100 人の 無症候性 COVID-19患者を、無作為化しました。
無作為化比較調査の結果：
研究チームは次のように結論付けました。
イベルメクチンは、「無症候性のSARS-CoV-2陽性患者の無作為化治療」において、「今回の臨床試験で、良好な効果が得られた」とのことです。
The treatment group
received a single dose of ivermectin along with supplements while the control arm received only supplements.These supplements included Zinc (30-50 mg/day) and Vitamin C (500 mg twice daily).
Ivermectin was dosed based on the following categories:
body weights of 45-64 kg, 65 to 84 kg,
or above 85 kg received (PO)9 mg, 12 mg or 150 μg/kg body weight of ivermectin, respectively.
The team discovered that
before the regimen was started (day 0),
there was no significant difference between CT-values in the two groups, suggesting that subjects in both groups had similar viral loads.
However, by the 72nd hour, after the regimen started,
an increase in CT-values was much higher in the ivermectin group than in the control group.
The study team concluded that
ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2 positive subjects,effectively resulting in fewer symptoms, lower viral load,
and reduced hospital admissions.This study was involved a few different universities, including:
Lebanese University, Beirut
Beirut Arab University
Lebanese International University
Rayak University Hospital
Ministry of Health, Beirut
Qatar UniversityAnother Positive Look for Ivermectin
While this study was small and the authors acknowledge that larger clinical trials warranted an overall reduction in viral load,reduced symptoms as compared to the control group,
and zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group),
the results were overall impressive.This is especially the case as the study focused on early treatment and a majority of the patients in this cohort end up doing well without treatment.